ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

AbCellera today announced new data on its PSMA x CD3 T-cell engagers, presented as a poster at the American Association for Cancer ResearchⓇ 116th Annual Meeting at the McCormick Place Convention ...

A new study published online in the Journal of Intensive Medicine on June 17, 2025, highlights early and dynamic alterations in lymphocyte subsets following sepsis in elderly patients and their ...

Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial. [212Pb]VMT-α-NET ...

SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (ADAG) and Third Arc Bio, Inc. (“Third Arc Bio”), today announced a licensing agreement under which ...

-- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- -- Management hosting webcast and conference call today at 1:30 p.m. ET / 10 ...

In a deal worth up to $840 million, Third Arc Bio Inc. is licensing Adagene Inc.’s Safebody technology platform to generate two masked CD3 T-cell engagers against unique tumor associated antigens.

Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study Patients received escalating ...

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...